CAR T-Cell Therapy

>

Latest News

FDA’s ODAC Votes Benefits of Ide-Cel Outweigh Risks in R/R Multiple Myeloma
FDA’s ODAC Votes Benefits of Ide-Cel Outweigh Risks in R/R Multiple Myeloma

March 15th 2024

The result of the FDA's Oncologic Drug Advisory Committee vote on idecabtagene vicleucel for the proposed indication is favorable.

When CAR T Fails in Myeloma, Can Nivolumab Help?
When CAR T Fails in Myeloma, Can Nivolumab Help?

March 13th 2024

CAR T Cell’s Promise: “[A] single infusion may... keep that cancer in remission.”
CAR T Cell’s Promise: “[A] single infusion may... keep that cancer in remission.”

March 12th 2024

FDA Grants Orphan Drug Designation to Novel CAR T-Cell Therapy in Colorectal Cancer
FDA Grants Orphan Drug Designation to Novel CAR T-Cell Therapy in Colorectal Cancer

March 4th 2024

Advancements in CAR T, GVHD Shine at 2024 TCT Tandem Meetings
Advancements in CAR T, GVHD Shine at 2024 TCT Tandem Meetings

February 26th 2024

Video Series
Video Interviews

More News